Orexo Issues New Shares
Stockholm - Swedish Orexo Pharmaceuticals AB has carried out a directed new share issue in mid-September in which the Swedish investor Catella Capital became a new owner. At the same time the life science investor HealthCap increased its investment in the company. The new issue generates total proceeds to Orexo of about Euro5 million. “The capital infusion allows us to further strengthen our product portfolio and advance our competitive market positions,” said Zsolt Lavotha, President and CEO of Orexo AB, a product-focused drug delivery company. Orexo develops documents and registers innovative pharmaceutical products with clinical benefits based on patented technology platforms.